Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 3 de 3
Filtrar
Más filtros











Base de datos
Intervalo de año de publicación
2.
Exp Hematol ; 100: 1-11, 2021 08.
Artículo en Inglés | MEDLINE | ID: mdl-34298117

RESUMEN

The clinical success of engineered, CD19-directed chimeric antigen receptor (CAR) T cells in relapsed, refractory B-cell acute lymphoblastic leukemia (B-ALL) has generated great enthusiasm for the use of CAR T cells in patients with cytogenetics that portend a poor prognosis with conventional cytotoxic therapies. One such group includes infants and children with mixed lineage leukemia (MLL1, KMT2A) rearrangements (MLL-r), who fare much worse than patients with low- or standard-risk B-ALL. Although early clinical trials using CD19 CAR T cells for MLL-r B-ALL produced complete remission in most patients, relapse with CD19-negative disease was a common mechanism of treatment failure. Whereas CD19neg relapse has been observed across a broad spectrum of B-ALL patients treated with CD19-directed therapy, patients with MLL-r have manifested the emergence of AML, often clonally related to the B-ALL, suggesting that the inherent heterogeneity or lineage plasticity of MLL-r B-ALL may predispose patients to a myeloid relapse. Understanding the factors that enable and drive myeloid relapse may be important to devise strategies to improve durability of remissions. In this review, we summarize clinical observations to date with MLL-r B-ALL and generally discuss lineage plasticity as a mechanism of escape from immunotherapy.


Asunto(s)
N-Metiltransferasa de Histona-Lisina/genética , Inmunoterapia Adoptiva , Proteína de la Leucemia Mieloide-Linfoide/genética , Leucemia-Linfoma Linfoblástico de Células Precursoras B/terapia , Animales , Antígenos CD19/genética , Antígenos CD19/inmunología , Reordenamiento Génico , N-Metiltransferasa de Histona-Lisina/inmunología , Humanos , Inmunoterapia Adoptiva/métodos , Proteína de la Leucemia Mieloide-Linfoide/inmunología , Leucemia-Linfoma Linfoblástico de Células Precursoras B/genética , Leucemia-Linfoma Linfoblástico de Células Precursoras B/inmunología , Resultado del Tratamiento , Escape del Tumor
3.
Cancer J ; 25(3): 178, 2019.
Artículo en Inglés | MEDLINE | ID: mdl-31135524
SELECCIÓN DE REFERENCIAS
DETALLE DE LA BÚSQUEDA